Clinical-stage BridgeBio Oncology Therapeutics, whose financial backers include Cormorant Asset Management, is going public ...

BridgeBio Oncology has entered a definitive merger agreement with Helix Acquisition Corp II, which will result in the ...

In a move straight out of 2021, BridgeBio Oncology is taking the SPAC route to the public markets in a deal with Helix ...

The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...

BridgeBio Oncology Therapeutics (BBOT), a company advancing small molecule therapeutics targeting RAS and PI3Ka malignancies, ...

This South San Francisco company would be the first Bay Area biotech company to go public this year, proving that the SPAC ...

BridgeBio Oncology has entered a definitive merger agreement with Helix Acquisition Corp II, which will result in the formation of a combined entity known as BridgeBio Oncology Therapeutics.

BridgeBio Oncology Therapeutics, a company working to advance the field of therapies addressing a validated but elusive group of cancer targets, has reached a deal to go public in a SPAC merger ...

BridgeBio Pharma (BBIO) stock in focus as its 2024 spinout BridgeBio Oncology merges with Helix to form go public on Nasdaq ...

For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. | For a while, special ...

BridgeBio Oncology Therapeutics to go public via merger with Helix Acquisition Corp. II SPAC, led by Bihua Chen's Cormorant, ...